MedWatch

Lundbeck: Pandemic and currency woes have led to setbacks

The lockdowns caused by the covid-19 pandemic will still affect Lundbeck's second quarter, and the company will also be affected by expiring patents, says Sydbank analyst Søren Løntoft Hansen.

Photo: Jens Dresling

Lundbeck's quarterly report is being released on Tuesday, and is expected to account for three months dominated by setbacks.

The patents for several drugs have expired, and lockdowns and infection risks are predicted to have reduced the number of patients that have started using Lundbeck's key products.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs